Introduction
Introduction

Tumour progression is a complex multistep process that depends on an evolving crosstalk between cancer cells and the surrounding stromal tissue. The microenvironment is now recognized as having a pivotal role in promoting cancer initiation, progression and dissemination to form metastases
. The invasion process involves extracellular matrix (ECM)-degrading proteases, particularly matrix metalloproteinases (MMPs) , that have been shown to be highly expressed and activated in the tumour microenvironment [2] , especially in highly aggressive malignant tumours [3, 4] . Activated [6, 7] , thus regulating ECM degradation and tumour cell invasion. [8] [9] [10] [11] and also several human tumour cells [12] [13] [14] [15] . Interestingly, TFPI-2, now considered to be a candidate tumour suppressor gene, has been shown to be down-regulated in particularly aggressive tumours [11, 13, 16] [16] [17] [18] [19] [20] [21] . In agreement with these studies, we have demonstrated that decreased TFPI-2 gene expression and hypermethylation are frequently associated with advanced stages of non-small cell lung cancer, particularly with lymph node invasion [15] .
fibroblasts, the major cell component of the microenvironment, actively contribute to tumour invasiveness by secreting a consistent amount of MMPs at the tumour-stroma interface. Moreover, this MMP synthesis could be increased by the ECM metalloproteinase inducer (EMMPRIN) expressed by cancer cells. Activation of zymogens (pro-MMPs) in the extracellular environment needs proteolytic cleavage of the aminoterminal prodomain [5] that depends on serine proteases, such as trypsin and plasmin, and also involves activated MMPs or membrane-anchored matrix metalloproteinases (MT-MMPs). Apart from tissue inhibitors of metalloproteinases (TIMPs) that are specific regulators of MMP activity, TFPI-2 (tissue factor pathway inhibitor-2), an inhibitor of serine proteases -particularly plasmin -could also regulate the activation of MMPs
TFPI-2 silencing increases
TFPI-2 is a 32 kD Kunitz-type serine proteinase inhibitor secreted into the ECM by a wide variety of human cells including endothelial cells, monocytes, fibroblasts, epithelial cells, smooth muscle cells, syncytiotrophoblast cells
in association with epigenetic changes. Hypermethylation of CpG islands of TFPI-2 promoter and histone deacetylation have frequently been correlated with transcriptional silencing of the TFPI-2 gene in cancer cells
The consequences of TFPI-2 down-regulation on MMP expression by both tumoural and stromal cells remain unclear and could have a key role in controlling tumour invasion by modifying the balance between ECM-degrading proteases and their inhibitors into the microenvironment. We therefore investigated the impact of stable TFPI-2 inactivation in NCI-H460 non-small lung cancer cells on their behaviour toward lung fibroblast cells. We applied the promising new micro-interfering RNA approach (miRNA) to trigger sequence-specific TFPI-2 RNA degradation and gene silencing. We studied the effects of TFPI-2 inactivation on tumour growth in a nude mice orthotopic model and then invasiveness, proliferation and adhesion properties of cancer cells to ECM proteins and their MMP expression pattern. We also evaluated whether TFPI-2 inactivation in cancer cells might be responsible for regulation of MMP synthesis by pulmonary fibroblasts.
Materials and methods
Cell cultures
The human non-small cell lung cancer cell line 
Identification of regulated signal transduction pathways
Preparation of tumour cell-conditioned medium
To examine miRNA-induced gene down-regulation, total mRNA and protein from the ECM of NCI-H460, miRNA-Neg, miRNA-1a and -1b, and miRNA-2a and -2b cells were extracted. Although the miRNA-Neg and miRNA-1a clones exhibited no
Fig. 1 TFPI-2 silencing in lung cancer cells by micro-RNA interference. (A) TFPI-2 transcript levels were quantified using real-time RT-PCR in non-small lung cancer cells stably transfected with recombinant plasmids containing miRNA inserts that target TFPI-2 mRNA in parental NCI-H460. The copy number of TFPI-2 transcripts was first normalized to 10 6 copies of ␤-actin mRNA and the percentage of TFPI-2 mRNA inhibition in miRNA clones was compared to parental NCI-H460. Data are presented as means Ϯ S.E.M. from four independent mRNA extractions and real-time RT-PCR performed in triplicate. (B) TFPI-2 protein expression in ECM from NCI-H460 non-small lung cancer cells and miRNA clones by immunoblotting using a rabbit polyclonal antibody against TFPI-2. (C) Immunofluorescence staining of parental NCI-H460 cells and miRNA-1b and -2b clones using a rabbit polyclonal antibody against TFPI-2 (original magnification, ϫ40). interference effect, significant inhibition of TFPI-2 transcripts was achieved in the miRNA-1b, -2a and -2b cell clones as demonstrated by RT and real-time PCR, with 91%, 73% and 93.5% inhibition, respectively, compared to parental NCI-H460 cells (Fig. 1A). As shown in Fig. 1B, TFPI-2 protein level was strongly decreased in the ECM of miRNA-1b and -2b cells, and to a lesser extent in miRNA-2a cell ECM. The presence of TFPI-2 triplets was demonstrated in the ECM of untransfected NCI-H460 and in miRNA-Neg and miRNA-1a transfected cells. Two clones, miRNA-1b and -2b, with the highest TFPI-2 inhibition were thus selected for further experiments, and immunofluorescence staining clearly showed the reduced expression of TFPI-2 in both these cell clones (Fig. 1C). In contrast, no variation in TFPI-2 expression was observed in miRNA-Neg cells compared to NCI-H460 parental cells. Therefore, miRNA-Neg was used as negative control. Transfection stability with miRNA was checked every month by measuring EmGFP fluorescence and the inhibition of TFPI-2 transcripts was monitored by real-time RT-PCR. No detectable loss of TFPI-2 inhibition was observed over a year.
Down-regulation of TFPI-2 promotes tumour progression in a nude mice orthotopic model
miRNA-Neg, miRNA-1b and -2b NCI-H460 cell suspensions containing a 99m
Tc-labelled tin colloid used as tracer were implanted intrabronchially with a catheter inserted into the trachea. The catheter position into the right main bronchus was checked using X-ray imaging and the punctual deposition of cells into the lung assessed by scintigraphy. Only one mouse died immediately after surgery and another one died during experimentation due to tumour progression. When cells were orthotopically implanted with 10 mM EDTA, lung tumours were obtained in 95% of mice after a 4-week period. Tumours were located in the lower and middle parts of the lung as demonstrated by tomography scanning (Fig. 2). Lung tumour volumes were calculated on axial transverse sections. The results showed an increase in tumour volumes with both miRNA-1b (P ϭ 0.05) and -2b (P ϭ 0.02) clones compared to miRNA-Neg cells.
TFPI-2 down-regulation promotes lung cancer cell migration and invasion without impact on cell proliferation
The migratory ability of miRNA-1b and -2b NCI-H460 clones through insert filters of 8 m pore size was significantly increased 1.7-fold (P Ͻ 0.001) and 1. 4 (Fig. 3A) . In both cases, the miRNA-1b cell clone exhibited greater migratory and invasion ability than miRNA-2b. Fig. 3B, cell (Fig. 3C) 
-fold (P Ͻ 0.05) respectively), compared to those of the miRNA-Neg clone. Down-regulation of TFPI-2 was also associated with a significant increase (P Ͻ 0.001) in the invasion of miRNA-1b (2.5-fold) and of -2b (1.8-fold) cell clones through Matrigel™, which mimics basement membrane components
Growth of miRNA clones and miRNA-Neg cells seeded at low density was then measured every 24 hrs over 96 hrs. As shown in
Down-regulation of TFPI-2 increases lung cancer cell adhesion to extracellular matrix proteins
To explore further the mechanisms by which TFPI-2 is able to regulate cell invasion, we investigated whether cell attachment to different ECM components was affected when this serine protease
Tc-labelled tin colloid and 10 mM EDTA was slowly injected into the right lobe. The scintigraphic assessment of the cell deposition into lung was then performed. Tumour progression was monitored using computed tomography scanning imaging over a 4-week period. Twenty minutes prior imaging, 100 mg/kg D-luciferin was injected i.p. to anesthetized mice. Lung tumour (T) volumes were measured on axial transverse sections. Each scanning image is representative of results obtained in nine animals per group. Tumour volume results are mean Ϯ S.E.M. (n ϭ 9). inhibitor was down-regulated. The results showed increased adhesion to fibronectin, vitronectin, laminin and collagen IV with both miRNA-1b and -2b clones compared to miRNA-Neg cells
TFPI-2 down-regulation modulates integrin expression on cell surface
To investigate whether the expression of integrins on cell surface could mediate cell-matrix adhesion and thus invasion process, we determined the integrin profiles of cells using various ␣ and ␤ subunit antibodies. Our data clearly demonstrated that down-regulation of TFPI-2 could promote expression of ␣1 subunit (P Ͻ 0.01) while ␤4 and ␣5␤1 were significantly decreased (P Ͻ 0.01) (Fig. 4) . In contrast, the expression of the other ␣ and ␤ integrins remained unchanged in miRNA-Neg, mi-RNA-1b and -2b clones.
Impact of TFPI-2 down-regulation on matrix metalloproteinase expression in lung cancer cells
Levels of MMP-1, -2, -3, -7, -9, -13, -14 and EMMPRIN transcripts
were quantified in miRNA-Neg, miRNA-1b and -2b clones using RT and real-time PCR (Fig. 5A) (Fig. 5B) . No significant differences were found in mRNA expression for MMP-9, -13, -14 and EMM-PRIN in either miRNA-1b or -2b compared to the control clone (Fig. 3A) . In contrast, MMP-7 and MMP-2 transcript levels were significantly decreased in miRNA-1b (P Ͻ 0.01) and -2b (P Ͻ 0.001 and P Ͻ 0.01, respectively) clones. As shown in Fig. 5(B) , MMP-7 protein expression was slightly decreased in both miRNA clones. 
Analysis of signalling pathways
Effects of conditioned media from TFPI-2 down-regulated non-small lung cancer cells on metalloproteinase expression in lung fibroblasts
Discussion
The relationship between TFPI-2 down-regulation, frequently associated with epigenetic changes and tumour aggressiveness, has been well documented in a wide variety of cancers [11, 18] [33, 34] and elevated expression of MMP-1 has been reported to be associated with poor prognosis in aggressive tumours [35] . Moreover, MMP-1 silencing has been shown to be correlated with decreased ability of chondrosarcoma cells to invade a type I collagen matrix [36] and melanoma cells to form metastases in mice [37] . Secretion of MMP-3 also correlates closely with tumorigenicity and invasiveness of human astrocytoma cells [38] , and migration of muscle cells was reduced when expression of MMP-3 was knocked down using siRNA [39] . The [40] . The ERK signalling pathway has been also implicated in the activation of many other MMP [41, 42] and it has been shown that down-regulation of this pathway inhibits migration and invasion of tumour cells [43, 44] [47] , and that TNF-␣ stimulates MMP-1 and MMP-3 mRNA expression by fibroblasts [48, 49] . Moreover, EGF can also enhance the transcriptional activity of EMMPRIN [50] , a cell surface glycoprotein that stimulates MMP and vascular endothelial growth factor (VEGF) synthesis of both tumour and stromal cells [51] 
